Abstract: Novel growth hormone conjugates comprising a growth hormone compound (GH) and a growth hormone binding protein (GHBP) are disclosed. The invention also encompasses a novel derivatization method for producing stable, long-lasting conjugate (hGH-GHBP) by site specific conjugation. The novel GH-GHBP conjugates have an extended half-life in circulation that facilitates therapeutic use of the protein. The GH-GHBP conjugates exhibit pharmacological properties such as increased functional in vivo half-life, improved renal filtration, improved protease protection and albumin binding.
Abstract: This invention provides antimicrobial compositions containing methylglyoxal and material with methylglyoxal contained (such as manuka honey). The antimicrobial activity of methylglyoxal, or material with a methylglyoxal presence, is maintained and/or enhanced by mixing methylglyoxal or material with a methylglyoxal presence with cyclodextrin. Methods of preparing such compositions, including powder composition, and methods of using such compositions are also provided.
Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Type:
Application
Filed:
April 6, 2011
Publication date:
October 27, 2011
Applicant:
UNIVERSITY HEALTH NETWORKS
Inventors:
Peter B. Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer, Guohua Pan
Abstract: Tetrapyrollic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl3.6H2O to oxidize the D ring and separating the resulting organic layer and drying.
Type:
Application
Filed:
February 19, 2009
Publication date:
October 27, 2011
Applicant:
Health Research, Inc.
Inventors:
Ravindra K. Pandey, Chao Liu, Mahabeer Dobhal, William Potter, Janet Morgan, Allan Oseroff, Stephanie Pincus
Abstract: Provided is an apparatus for assessing interface integrity between a medium and an implant. A first signal is translated from a motion of an impact body during impact with an abutment connected to the implant. In some embodiments, the first signal is filtered using a zero phase shift filter and then used for assessing the interface integrity. Since no phase shift is introduced, the interface integrity is accurately assessed. In another embodiment, the apparatus maintains a system model for impacting the impact body against the abutment. The apparatus analytically determines an interface property by applying a system property that has been determined to the system model. An accurate system model allows for an accurate assessment. According to another broad aspect, there is provided a method of conducting the impact test. According to the method, a person ensures that the impact body impacts against a consistent portion of the abutment.
Type:
Application
Filed:
August 17, 2007
Publication date:
October 27, 2011
Applicants:
CARITAS HEALTH GROUP, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Gary Faulkner, Donald Wayne Raboud, Ryan Clair Swain, Johan Francis Wolfaardt
Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for inhibiting or treating inflammatory lung disease by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
Type:
Grant
Filed:
October 7, 2003
Date of Patent:
October 25, 2011
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.
Type:
Grant
Filed:
June 7, 2005
Date of Patent:
October 25, 2011
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Abstract: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the ?-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the ?-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone.
Type:
Grant
Filed:
May 15, 2009
Date of Patent:
October 25, 2011
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Mariusz W. Szkudlinski, Bruce D. Weintraub, Mathis Grossmann
Abstract: Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
October 25, 2011
Assignee:
Health Research, Inc.
Inventors:
Fengzhi Li, Ali Ghadersohi, Pasha Apontes
Abstract: The invention can be summarized as follows. There is provided a method for amplifying hypomethylated genomic nucleotide sequences and/or hypermethylated genomic nucleotide sequences and comparing the methylation state between different samples, for example control and test samples. Also disclosed is a microarray based method for analyzing hypo and/or hypermethylated genomic nucleotide sequence. Further, kits comprising reagents for practicing the method are provided.
Abstract: Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.
Type:
Grant
Filed:
April 27, 2009
Date of Patent:
October 25, 2011
Assignee:
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Jay A. Berzofsky, SangKon Oh, Ira Pastan
Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.
Type:
Grant
Filed:
June 15, 2010
Date of Patent:
October 25, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Stephen H. Leppla, Yogendra Singh, Kurt Klimpel, Rachel Schneerson, John B. Robbins
Abstract: Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure of wherein the presence of each of R1 and R2 is optional and R1 and R2 are each independently selected from alkyl, substituted alkyl, heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, halogen, hydroxy, or amino.
Type:
Grant
Filed:
December 9, 2004
Date of Patent:
October 25, 2011
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.
Type:
Grant
Filed:
September 6, 2006
Date of Patent:
October 25, 2011
Assignees:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Dana Farber Cancer Institute, Inc.
Inventors:
Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Chih-Chin Huang, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
Abstract: A device for facilitating application of a plastic film to skin, said plastic film being a component in a wound dressing or other medical article, comprising a stiffening layer removably attached to one side of said film. Two grip handles are arranged on the stiffening layer, which is divided in two regions, arranged on opposite side of a fictitious line crossing over the film. A first one of said grip handles is fastened on one of said regions of the stiffening layer in at least parts of an elongated area and the rest of said grip handle is free and extends from said elongated area over said one region of the stiffening layer with its centre line in a first direction towards one end of the film. The other grip handle is arranged in the same way on the other of said regions of the stiffening layer and extends in an opposite direction to the first grip handle.
Abstract: A hydromagnetic joint includes a first joint part having a first magnetic element with a magnetically charged surface, and a first buoyant element coupled with the first magnetic element, and a second joint part including a second magnetic element having a second magnetically charged surface that opposes the first magnetically charged surface of the first magnetic element, and a second buoyant element coupled with the second magnetic element. The hydromagnetic joint has a liquid disposed between the first and second joint parts. The first and second joint parts are moveable relative to one another and are in fluid communication with the liquid. The first and second magnetically charged surfaces have a common polarity and repel one another.
Type:
Application
Filed:
February 21, 2011
Publication date:
October 20, 2011
Applicant:
Fleischmann's Institute of Science & Health
Abstract: Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject.
Abstract: There is herein described medical apparatus. More particularly, there is herein described medical apparatus capable of adapting and/or conforming to a non-planar surface on a patient's body.